Modality
Peptide
MOA
SOS1i
Target
SHP2
Pathway
JAK/STAT
Prostate Ca
Development Pipeline
Preclinical
Jan 2022
→ Mar 2027
PreclinicalCurrent
NCT04412401
664 pts·Prostate Ca
2022-02→TBD·Completed
NCT08172774
785 pts·Prostate Ca
2022-01→2027-03·Completed
1,449 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-03-1611mo awayInterim· Prostate Ca
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
Preclinical
Complet…
Preclinical
Complet…
Catalysts
Interim
2027-03-16 · 11mo away
Prostate Ca
Completed|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04412401 | Preclinical | Prostate Ca | Completed | 664 | SeizFreq |
| NCT08172774 | Preclinical | Prostate Ca | Completed | 785 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| REG-647 | Regeneron | Preclinical | SMN2 |